Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.

Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics is a biotechnology company focused on developing targeted protein degradation therapies.

Monte Rosa Therapeutics

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. Monta Rosa’s QuEEN™ (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN™ discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas. Monte Rosa has developed the industry’s leading pipeline of MGDs.

RTW Investments

Cormorant Asset Management

Fidelity

Google Ventures

New Enterprise Associates

Cambridge Asset Management

Casdin Capital

HBM Healthcare Investments AG

Fidelity Management and Research Company

Aisling Capital

Amzak Health Investors

Avoro Capital Advisors

Today we share our second quarter 2024 financial results and corporate update. View the full press release here: https://bit.ly/3WDjih9

Step into the future with Monte Rosa's dynamic Data Sciences team! #DataSciences #AI #Biotech

We’re pleased to share this brand new scientific review of VAV1 published in Trends in Immunology, highlighting the therapeutic potential of novel approaches targeting VAV1 for autoimmune diseases, including our VAV1 molecular glue degrader MRT-6160. 

Read the scientific review here: https://bit.ly/4c6BO6Z

Every year Monte Rosa welcomes the brilliant scientists of tomorrow. Their curiosity, innovation, and enthusiasm help shape our culture. Learn more about the Monte Rosa Internship experience. #NationalInternDay #Biotech

Starting off the summer with good times and great people. 
#Summer #GoodTimes

Join our CEO Markus Warmuth next week for a fireside chat at the virtual UBS TPD day. Learn more here: https://bit.ly/3zuVS5I

	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue
cost of revenue	72K -	537K 645.83%	2.13M 297.02%	8.56M 301.45%	6.22M 27.30%
gross profit	-72K -	-537K 645.83%	-2.13M 297.02%	-8.56M 301.45%	-6.22M 27.30%
selling and marketing expenses
general and administrative expenses	644K -	4.00M 521.89%	15.73M 292.68%	27.32M 73.73%	32.04M 17.26%
selling general and administrative expenses	644K -	4.00M 521.89%	15.73M 292.68%	27.32M 73.73%	32.04M 17.26%
research and development expenses	7.35M -	24.00M 226.60%	57.16M 138.10%	85.06M 48.83%	105.05M 23.50%
other expenses	276K -	-7.68M 2,882.61%	-960K 87.50%
cost and expenses	7.99M -	28.01M 250.39%	72.88M 160.20%	112.38M 54.20%	143.31M 27.52%
operating expenses	7.99M -	28.01M 250.39%	72.88M 160.20%	112.38M 54.20%	137.09M 21.98%
interest expense	1K -			3.76M -
ebitda	-7.65M -	-27.27M 256.72%	-72.72M 166.62%	-112.50M 54.71%	-137.09M 21.85%
operating income	-7.99M -	-28.01M 250.39%	-72.88M 160.20%	-112.38M 54.20%	-143.31M 27.52%
depreciation and amortization	348K -	735K 111.21%	162K 77.96%	-119K 173.46%	6.22M 5,328.57%
total other income expenses net	254K -	-7.87M 3,198.03%	-1.08M 86.33%	3.88M 460.87%	8.30M 113.67%
income before tax	-7.74M -	-35.88M 363.55%	-73.96M 106.13%	-108.50M 46.71%	-135.01M 24.44%
income tax expense	277K -	189K 31.77%	-2.02M 1,166.67%	-3.88M 92.61%	338K 108.70%
net income	-8.02M -	-36.07M 349.89%	-71.94M 99.46%	-104.62M 45.42%	-135.35M 29.38%
weighted average shs out	44.00M -	44.00M 0%	46.54M 5.76%	47.23M 1.49%	51.40M 8.83%
weighted average shs out dil	44.00M -	44.00M 0%	46.54M 5.76%	47.23M 1.49%	51.40M 8.83%
eps	-0.18 -	-0.82 355.56%	-1.55 89.02%	-2.22 43.23%	-2.63 18.47%
epsdiluted	-0.18 -	-0.82 355.56%	-1.55 89.02%	-2.22 43.23%	-2.63 18.47%

COM:MONTEROSATX

Monte Rosa Therapeutics

Last Close

8.84

05/11 21:00

Market Cap

238.49M

Beta: -

Volume Today

683.62K

Avg: -

Preview